82% of Global LPs to Increase Exposure to Private Credit in Next Three Years, CSC Research Finds
23.9.2025 16:00:00 EEST | Business Wire | Press release
More than four fifths (82%) of limited partners (LPs) say they expect to increase allocations to private credit over the next three years, according to a new international study by CSC, the leading provider of global business administration and compliance solutions. Of these LPs, around two fifths (42%) expect “significant” growth in private credit exposure, underscoring the momentum and positive investor sentiment towards the asset class.
The research that canvassed the views of 300 general partners (GPs) and 200 limited partners (LPs) in Europe, Asia Pacific, and North America, found that portfolio diversification was the primary motive behind greater allocation (according to 76% of LPs), ahead of attractive returns (36%).
Private credit GPs are also bullish. The study, commissioned by CSC to inform its new report, “Private Credit 2025: Scaling Global Strategies Through Operational Excellence,” found three fifths (59%) of GPs forecasting AUM growth of 6–10% over a three-year horizon and 31% expecting growth above 10%.
“Private credit has exploded into the mainstream, becoming a truly global, multijurisdictional phenomenon that looks set to attract more and more investor capital,” said Marshall Saffer, managing director, Funds and Capital Markets at CSC. “As a business, we’re seeing first-hand how private credit has evolved, including innovation in structuring and cross-border strategies, and we’re well positioned to help GPs capitalize on strong demand.”
Growth driven by strategy shifts and cross-border expansion
CSC’s study found senior debt and asset-backed finance emerging as the most attractive underlying strategies, with distressed debt ranked lowest in expected growth. Cross-border lending is another major growth area, with 79% of GPs expecting international activity to increase significantly.
However, as the private credit sector grows, administrative complexity is increasingly taking its toll, especially for cross-border strategies where reporting, risk transparency, and operational readiness are under greater scrutiny.
“Private credit’s fast growth presents implicit challenges to operating models for fund managers, and imposes considerable demands on them and other stakeholders, particularly when investing in multiple jurisdictions and across borders,” said Constantinos Kleanthous, managing director, APAC at CSC. “As our study found, GPs have voted with their feet when it comes to outsourcing operational support to dedicated third-party specialists—and even more for functions like loan agency.”
CSC’s report found that 91% of LPs believe GPs who outsource to specialist service providers deliver enhanced reporting. Respondents cited SPV administration, collateral management, and loan agency as crucial in managing fund complexity and enhancing transparency.
As private credit cements its place in global portfolios, the research makes clear that growth must be matched with operational strength. GPs with the right infrastructure, and the right specialist partners will be best placed to seize the opportunity ahead.
For a full copy of “Private Credit 2025: Scaling Global Strategies Through Operational Excellence,” download it at cscglobal.com/service/campaigns/private-credit-2025.
About CSC
CSC is the trusted partner of choice for more than 90% of the Fortune 500®, more than 90% of the 100 Best Global Brands (Interbrand®), and more than 70% of the PEI 300. We are the world’s leading provider of global business administration and compliance solutions, specialized administration services to alternative asset managers across a range of fund strategies, transactions involving capital markets participants in both public and private markets, domain name system management and digital brand and fraud protection, and corporate tax software solutions. Founded in 1899 and headquartered in Wilmington, Delaware, USA, CSC prides itself on being privately held and professionally managed for more than 125 years. CSC has office locations and capabilities in more than 140 jurisdictions across Europe, the Americas, Asia Pacific, and the Middle East. We are a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. We are the business behind business®. Learn more at cscglobal.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250923262106/en/
Contacts
Citigate Dewe Rogerson (CDR)
Hassan Ali | Thomas Dalton
cscteam@cdrconsultancy.com
CSC
Laura Crozier
PR Manager
laura.crozier@cscglobal.com
CSC News Room -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cscglobal.
com%2Fservice%2Fpress%2F&esheet=54327702&newsitemid=20250923262106&lan=en-US&anc
hor=CSC+News+Room&index=3&md5=244f3b008c79b0d54ac0f3135440b491
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom